Last $0.62 USD
Change Today +0.015 / 2.50%
Volume 286.6K
GCVRZ On Other Exchanges
Symbol
Exchange
EN Paris
EN Paris
New York
OTC US
BrsaItaliana
Mexico
Frankfurt
Frankfurt
NASDAQ GM
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi cvr (GCVRZ) Snapshot

Open
$0.60
Previous Close
$0.60
Day High
$0.62
Day Low
$0.59
52 Week High
11/7/13 - $2.06
52 Week Low
03/31/14 - $0.30
Market Cap
--
Average Volume 10 Days
574.5K
EPS TTM
--
Shares Outstanding
238.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SANOFI CVR (GCVRZ)

sanofi cvr (GCVRZ) Details

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances and collaborations with Bristol-Myers Squibb, Regeneron, Warner Chilcott, Regulus Therapeutics Inc., Medtronic, Inc., UCB S.A., and Illumina, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1970

sanofi cvr (GCVRZ) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €3.0M
Compensation as of Fiscal Year 2013.

sanofi cvr (GCVRZ) Key Developments

Merck & Company and Sanofi Announce a License Application for Investigational Pediatric Hexavalent Vaccine

Merck & Company and Sanofi announced a license application for the company's investigational pediatric hexavalent vaccine to treat six diseases was accepted for review by the U.S. Food and Drug Administration. If approved, it would be the first pediatric vaccine to help protect against six diseases: diphtheria, tetanus, whooping cough, polio types 1, 2 and 3, disease cause by Haemophilus influenza type B and hepatitis B. In a phase III study, the drug, known as DTaP5-IPV-Hib-HepB1, was given to infants ages 2, 4 and 6 while other children received Sanofi Pentacel 2 and Merck's Recombivax HB treatments that are already licensed.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks. Secondary objectives of the study will evaluate the long-term safety and efficacy of dupilumab up to 52 weeks. The trial will enroll approximately 700 adult patients. The LIBERTY AD Phase 3 clinical program will consist of at least five trials of patients with moderate-to-severe AD at sites worldwide.

Actavis Reportedly Among Bidders For Omega Pharma

Actavis plc (NYSE:ACT) is known to be among the bidders for Omega Pharma NV, Bloomberg reported. Omega is expected fetch in excess of €4 billion or $5.1 billion. Others bidders in race for Omega are Perrigo Company Public Limited Company (NYSE:PRGO), Sanofi (ENXTPA:SAN) and Boehringer Ingelheim GmbH. The final offers for Omega are due in early November, 2014. The bidders are known to be carrying out due diligence for the sale handled by Morgan Stanley. Actavis’s shares were up $1.94 or 0.86% on a volume of 1.70 million shares.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GCVRZ:US $0.62 USD +0.015

GCVRZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.29 USD +0.77
Amgen Inc $147.26 USD +0.01
Bayer AG €105.85 EUR -0.81
Gilead Sciences Inc $110.71 USD +3.53
Novo Nordisk A/S kr267.10 DKK -2.40
View Industry Companies
 

Industry Analysis

GCVRZ

Industry Average

Valuation GCVRZ Industry Range
Price/Earnings 25.3x
Price/Sales 3.1x
Price/Book 2.0x
Price/Cash Flow 15.2x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI CVR, please visit www.sanofi-aventis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.